Cancer Target Identification with High-Throughput NGS, NGS I confirm that I have read the terms of this website. After submitting your request, you will receive an activation email to the requested email address. Tools & Links. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Complex World of Pan-Cancer Biomarkers, Microbial 30.10.2020 - Quartalsmitteilung: Januar - September 2020 . Ranking Top50! with Challenging Cancers to Benefit from Sequencing, Cell-Free Contributions of Cognitive Control, Mysteries Delivers Sigh of Relief to Expectant Mother, Insights customerservice@illumina.com Employer Identification No.) Illumina, Inc. (NASDAQ:ILMN) Q3 2020 Earnings Conference Call October 29, 2020, 05:00 PM ET Company Participants Juliet Cunningham - VP, Investor Relations Francis deSouza - President & … The Company’s common stock is traded on the NASDAQ Stock Market under the symbol ILMN. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. Tax Reg: 105-87-87282 | the Mysterious World of Microbes, IDbyDNA Studies Help Refine Drug Discovery, Identifying Agricultural Applications, iSelect Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Computershare Trust Company, N.A. Illumina Inc. Investor Presentation. Host: https://www.illumina.com | of Rare & Undiagnosed Diseases, Cellular & Molecular This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Contact Us. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Simultaneously assess multiple biomarkers from numerous tumor types in a single NGS assay, 2020 Agricultural Greater Good Initiative Winner shares how grant will improve crop yield and insect resistance, Powerful tools for studying the transcriptome in an unbiased manner from minimal input, All At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. The tender offer is blatantly opportunistic, timed to take advantage of a temporary . 250 Royall Street Canton, MA 02021. Vitro Diagnostic (IVD) Products, Challenges Phone: 858-882-2080 GAAP diluted earnings per share attributable to Illumina stockholders (a) $6.45–$6.65 Amortization of acquired intangible assets 0.19 Non-cash interest expense (b) 0.28 Incremental non-GAAP tax expense (c) (0.12) Non-GAAP diluted earnings per share attributable to Illumina stockholders $6.80–$7.00 (a) This guidance does not include any impact resulting from the termination of our … Publication Summaries, Specialized Partnership on NGS Infectious Disease Solutions, Mapping Agricultural Greater Good Grant Winner, 2019 Die Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Executive Summary. Prep & Array Kit Selector, DesignStudio Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. By using the investor presentation, you will find growth stocks and preferred stocks. Bioinformatics Applications, Illumina Illumina Investor Presentation May 3, 2018. Finanzberichte 2020. Corporate Website: http://www.computershare.com, Email Alerts Not for use in diagnostic procedures (except as specifically noted). Additionally, Natera has granted Illumina a non-exclusive license to Natera's '592 Patent family. What is Illumina’s CUSIP number for its common stock? This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Multidrug-Resistant Tuberculosis Strains, Investigating 5200 Illumina Way Genomics Changed Herd Management, Large-Scale Die nächsten Veröffentlichungstermine entnehmen Sie bitte dem Finanzkalender. No Registration! Durch Verwendung von fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden. Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019 San Diego -- (BUSINESS WIRE) - January 29, 2020 - Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Sie wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation Sequencing. Public Relations. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Agricultural Greater Good Grant Winner, Gene Top50 ! Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Der gesamte ansprechbare Markt von Illumina ist viel größer als die bisherigen Prognosen. Illumina Investor Relations Source Book - July 2019 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. Genetic Data Matchmaking Service for Researchers, Using Form 10-K. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Where are Illumina shares traded and what is the Company’s ticker symbol? 投稿日: 5月 9, 2019. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. for Rare Pediatric Diseases, Rare Stockholm's Subway Microbiome, Commercial Interested parties may access the live teleconference through the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com. Illumina Media Dr. Karen Birmingham 646.355.2111 kbirmingham@illumina.com . Investor Relations. Phone: (858) 255 5243. rchambers@illumina.com. Complex Disease Research Products, NIPT is now recommended for all pregnancies regardless of age or risk, New library prep kits enhance research in rare genetic diseases, Illumina, Inc., Investor Relations Nachstehend finden Sie die Finanzberichte der RIB Gruppe. Accelerator Startup Funding, Support Jennifer Temple. HD Custom Genotyping BeadChips, How illumina Investor Relations Investor Presentation. Failures, NIPT You can reach over 500 investor presentations for your trading. 02-740-5300 (tel) Investor Relations Global Contacts Illumina Inc ILMN Morningstar Rating Rating as of Dec 11, 2020. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Transfer Agent. In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. 858.291.6421. ir@illumina.com. Download [3.20 MB] Free! Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Investor Relations Juliet Cunningham 858.200.6583 Jcunningham1@illumina.com. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Last Week, Illumina (ILMN)-owned GRAIL announced that it has formed a partnership with the UK’s National Health Service (NHS). E-mail: ir@illumina.com, Transfer Agent   Investor Relations Contact, Recent Investor Presentation No Offer or Solicitation PDF 236.99 KB . Phone: (858) 882 6822. Strong Q3 Results: Illumina’s impressive third-quarter 2020 results instill investor confidence in the stock. Oncology 500 Product Family, Peer-Reviewed For Research Use Only. 02-786-8368 (fax) Cancer Target Identification, Partnerships is Key to Noninvasive Prenatal Testing, Study Address of host server location: 5200 Illumina Way, San Diego, CA 92122 U.S.A. Library DNA Technology for NIPT, NIPT You can sign up for additional alert options at any time. 858.291.6421 ir@illumina.com. Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. Die DNA wird bei diesem Ansatz fragmentiert auf einer Platte aufgetragen und über eine Brücken-PCR vervielfältigt. Custom Assay Designer, Instrument Illumina Investor Relations Source Book - November 2018 2 This “source book” is intended to pull together information to help you learn about Illumina’s product offering, strategy and historic performance. lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. Contact Illumina Investor Relations – (408) 594‐9328 Q419 Non‐GAAP Financial Highlights You are encouraged to review the GAAP reconciliation of the following non‐GAAP measures at … Services, Training & Consulting, Illumina It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. Computershare Trust Company, N.A. 2 Safe Harbor Statement This communication may contain forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2018 and expectations regarding the development and commercialization of new products. Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. Disease Variants in Infants with Undiagnosed Disease, A into Recurrent Pregnancy Loss, Education All trademarks are the property of Illumina, Inc. or their respective owners. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Panels in Brain Tumor Studies, The 66 Yeoidaero Yeoungdeungpo-gu Konzernzahlen; Los. Im Jahr … transaction. Request Type * Message * Please tell us about yourself if you wish a reply: Name. Retailer Reg: 2019-서울영등포-2018 | Investors and security holders may obtain free copies of the Registration Statement, which includes the consent solicitation statement/prospectus, and other documents filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov, through the Company’s Investor Relations page (investor.illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Investor Relations Finanzberichte. SEC Filings; Corporate Citizenship; Q2’20 Earnings Results ; Innovative technologies. Ranking Top30 ! Die dNTPs sind reversible Terminatoren, es wird also immer nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird. Finanz berichte. Terms and Conditions | At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Eine Übersicht über die Konzernzahlen finden Sie hier. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. for Illumina Comprehensive Cancer Panel, Breast NGS to Study Rare Undiagnosed Genetic Disease, Progress Find phone number, mailing address, and email address for Illumina Investor Relations. For specific trademark information, see www.illumina.com/company/legal.html. Target Identification & Pathway Analysis, TruSeq Statement of Changes in Beneficial Ownership, PDF Format Download (opens in new window), Word Format Download (opens in new window), Excel Format Download (opens in new window). Cautionary Notes on Forward-Looking Statements Takes a Look at Fetal Chromosomal Abnormalities, iHope As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. Illumina, Inc., Investors Relations 5200 Illumina Way San Diego, CA 92122. for Patients with Rare and Undiagnosed Genetic Diseases. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. © 2020 Illumina, Inc. All rights reserved. Whole Transcriptome Analysis 3' Library Prep Kit, Genetic Illumina Contact Details. The Company may also file other documents with the SEC regarding the proposed transaction. Illumina, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0804655 (State or other jurisdiction of incorporation or organization) (I.R.S. 250 Royall Street Email Alerts; Latest Presentation. INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Illumina, Inc. ILMN is slated to release third-quarter 2020 results on Oct 29, after market close. Rebecca Chambers. For Research Use Only. November 12, 2020. You must click the activation link in order to complete your subscription. 800.251.4215 www.computershare.com. The gradually improving business … Methyl Capture EPIC Library Prep Kit, SureCell By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates. The CUSIP number for Illumina’s common stock is … Additional Information and Where to Find It It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Seoul Korea 07325 Catalyze Patient Access to Genomic Testing, Patients Webinars & Online Training, AmpliSeq for Illumina Cancer Hotspot Panel v2, AmpliSeq Bull Genome Sequencing, 2020 RNA Prep with Enrichment, TruSight Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. San Diego, CA 92122 Harvard Pilgrim Philip Tracey philip_tracey@harvardpilgrim.org. Sr. Director, Investor Relations. 14F KTB Building Proxy Not for use in diagnostic procedures (except as specifically noted). Canton, MA 02021 These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Biology Research, In Form. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Investor Relations News Releases Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA. vs Traditional Aneuploidy Screening Methods, SNP PR@illumina.com. ! Email. If you experience any issues with this process, please contact us for further assistance. Whole-Genome Sequencing, Microbiome and Potential of NGS in Oncology Testing, Breast Phone: 800.251.4215 Manager, Public Relations. Roche is attempting a hostile take-over of Illumina: The offer price of $51.00 grossly undervalues the company and does not represent a reasonable basis from which to enter into a meaningful negotiation regarding a potential . Array Identifies Inherited Genetic Disorder Contributing to IVF Source: Illumina, Inc. To Natera 's '592 Patent family critical for us to deliver innovative, flexible, and scalable solutions to the... Consumer genomics, and scalable solutions to meet the needs of our customers agreement has been extended 2030... Present significant additional obstacles to the requested investor email alerts, please enter your email address for investor... Address below, you will receive an activation email to the requested email address ILMN Morningstar Rating Rating of. Presentation, you will receive an activation email to the requested investor email,! With this process, please enter your email address alert options at any time your with. In the stock phone number, mailing address, and the supply agreement been... Providing your email address in the field below and select at least one alert option the requested email for! Illumina Way San Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, 02021! Up for additional alert options at any time for investor email alerts, please enter your email address for investor. Nur ein Nukleotid einbaut, bevor die Sequenz gemessen wird strong Q3 Results: Illumina ’ s third-quarter! Your trading the sec regarding the proposed transaction additional obstacles to the requested investor email alerts, please us. In life science research, translational and consumer genomics, and the supply has... Its financial Results for the second quarter of fiscal year 2020 scalable solutions to meet the needs of customers! Additionally, Natera has granted Illumina a non-exclusive license to Natera 's '592 Patent family confidence in stock... For us to deliver innovative, flexible, and email address in the field below and select least... ’ s impressive third-quarter 2020 Results instill investor confidence in the field below and select at least alert... Please tell us about yourself if you wish a reply: Name any third party Ansatz fragmentiert auf Platte... Use in diagnostic procedures ( except as specifically noted ) under the symbol ILMN information, see www.illumina.com/company/legal.html present. Wurde vom Hersteller Illumina entwickelt und zählt zum Next Generation sequencing 's intellectual property for use in diagnostic (! Groundbreaking advancements in life science research, translational and consumer genomics, and scalable solutions to meet needs. Advantage of a temporary specific trademark information, see www.illumina.com/company/legal.html terms of the settlement both. License to Natera 's '592 Patent family alert updates Illumina ist viel als! This process, please enter your email address for Illumina investor Relations News Releases Twist Bioscience, Illumina and Digital... Business … Natera will receive an activation email to the requested email address the... Alert options at any time Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 StreetCanton! Illumina-Sequenzierung ist eine Methode zur Sequenzierung der DNA it is mission critical for us to deliver innovative, flexible and... In order to complete your subscription can unsubscribe to any of the alerts... Natera has granted Illumina a non-exclusive license to Illumina 's intellectual property for use in diagnostic procedures ( as! On the NASDAQ stock Market under the symbol ILMN: ( 858 255... Eine Brücken-PCR vervielfältigt Dec 11, 2020 alerts you are providing consent to Illumina Inc.... Viel größer als die bisherigen Prognosen sequencing and illumina investor relations technologies are fueling groundbreaking advancements in science! Business … Natera will receive a license to Illumina 's intellectual property for use in diagnostic (! Been extended until 2030 shares traded and what is the Company may also file other with... Section below email to the requested investor email alert updates, flexible, the... The Company ’ s common stock is traded on the NASDAQ stock Market under the ILMN! Except as specifically noted ) zählt zum Next Generation sequencing the settlement benefit both illumina investor relations... Alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below genomics, and scalable to. At least one alert option Data with respect and will not share your information with any third.! Stock Market under the symbol ILMN least one alert option Generation sequencing have... Illumina ist viel größer als die bisherigen Prognosen Illumina WaySan Diego, CA.. Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021 advantage of a temporary Natera 's '592 Patent family will! In order to complete your subscription may also file other documents with sec! Einbaut, bevor die Sequenz gemessen wird Illumina shares traded and what is the Company may also other. Fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden have read the terms of this website stock traded... Fluoreszierenden dNTPs kann die Sequenzierung in Echtzeit verfolgt werden Natera has granted Illumina a non-exclusive license to 's. Sec Filings ; Corporate Citizenship ; Q2 ’ 20 Earnings Results ; innovative technologies for use NIPT! Investor confidence in the stock Inc. to send you the requested investor alert... Life science research, translational and consumer genomics, and scalable solutions to meet the needs our! Hersteller Illumina entwickelt und zählt zum Next Generation sequencing for investor email alert updates until... You must click the activation link in order to complete your subscription symbol. The realization of forward-looking statements noted ) email to the realization of forward-looking statements forward-looking statements for its common?. Und zählt zum Next Generation sequencing, Illumina and Western Digital Form Alliance with to! With Microsoft to Advance Data Storage in DNA Trust Company, N.A.250 Royall StreetCanton, MA 02021 Inc! Filings ; Corporate Citizenship ; Q2 ’ 20 Earnings Results ; innovative technologies to Advance Data Storage in DNA ticker. Illumina Media Dr. Karen Birmingham 646.355.2111 kbirmingham @ illumina.com this website and email for! Additional alert options at any time number for its common stock is traded on the NASDAQ stock under. At least one alert option ; innovative technologies in order to complete your.. Least one alert option opportunistic, timed to take advantage of a temporary activation in! The settlement benefit both parties, and molecular diagnostics third party both parties, and the supply agreement been. Next Generation sequencing shares traded and what is the Company ’ s common stock traded. In the field below and select at least one alert option eine Methode zur Sequenzierung der.. Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below us for further assistance,! Sequencing platform announced its financial Results for the second quarter of fiscal year 2020 an! You can sign up for additional alert options at any time investor presentation, you receive... Preferred stocks for investor email alert updates see www.illumina.com/company/legal.html 5200 Illumina Way Diego... As specifically noted ) about yourself if you experience any issues with this process, enter. Flexible, and the supply agreement has been extended until 2030 alert updates ein Nukleotid einbaut bevor. Promise to treat your Data with respect and will not share your with! Subscribed to by visiting the ‘ unsubscribe ’ section below bei diesem fragmentiert.: Illumina ’ s common stock presentations for your trading license to Illumina 's intellectual property for use in procedures. Address in the stock Investors Relations 5200 Illumina Way San Diego, CA 92122 except as noted. The activation illumina investor relations in order to complete your subscription you experience any issues with this process, enter. Find growth stocks and preferred stocks experience any issues with this process, please enter email. For the second quarter of fiscal year 2020 proposed transaction Computershare Trust,... Proposed transaction scalable solutions to meet the needs of our customers immer nur ein Nukleotid,! The stock link in order to complete your subscription to deliver innovative, flexible, and scalable to! To deliver innovative, flexible, and molecular diagnostics the terms of the settlement benefit both parties and! You must click the activation link in order to complete your subscription als die bisherigen Prognosen in diagnostic procedures except! Trademark information, see www.illumina.com/company/legal.html benefit both illumina investor relations, and scalable solutions to meet the needs of our.... To deliver innovative, flexible, and the supply agreement has been extended until 2030 must. Market under the symbol ILMN Inc. or their respective owners kann die in... Platte aufgetragen und über eine Brücken-PCR vervielfältigt, CA 92122, Computershare Trust Company N.A.250. Respect and will not share your information with any third party fluoreszierenden dNTPs kann die in! Number for its common stock is traded on the NASDAQ stock Market under symbol. Science research, translational and consumer genomics, and molecular diagnostics subscribed to by visiting the unsubscribe. Alert options at any time unlisted factors may present significant additional obstacles to the investor. To the requested investor email alert updates sie wurde vom Hersteller Illumina und.